메뉴 건너뛰기




Volumn 29, Issue 10, 2009, Pages 1175-1181

Effect of saquinavir-ritonavir on cytochrome P450 3A4 activity in healthy volunteers using midazolam as a probe

Author keywords

Cytochrome P450; Drug interaction; Midazolam; Ritonavir; Saquinavir

Indexed keywords

ALPHA HYDROXYMIDAZOLAM; CYTOCHROME P450 3A; MIDAZOLAM; RITONAVIR PLUS SAQUINAVIR;

EID: 70349670588     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.29.10.1175     Document Type: Article
Times cited : (26)

References (21)
  • 1
    • 0030895312 scopus 로고    scopus 로고
    • Protease inhibitors in patients with HIV disease: Clinically important pharmacokinetic considerations
    • ▶1. Barry M, Gibbons S, Back D, Mulcahy F. Protease inhibitors in patients with HIV disease: clinically important pharmacokinetic considerations. Clin Pharmacokinet 1997;32:194-209.
    • (1997) Clin Pharmacokinet , vol.32 , pp. 194-209
    • Barry, M.1    Gibbons, S.2    Back, D.3    Mulcahy, F.4
  • 2
    • 0031024382 scopus 로고    scopus 로고
    • Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4: Potential contribution to high first-pass metabolism
    • Fitzsimmons ME, Collins JM. Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4: potential contribution to high first-pass metabolism. Drug Metab Dispos 1997;25:256-266
    • (1997) Drug Metab Dispos , vol.25 , pp. 256-266
    • Fitzsimmons, M.E.1    Collins, J.M.2
  • 3
    • 0030852009 scopus 로고    scopus 로고
    • Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir
    • ▶3. Eagling VA, Back DJ, Barry MG. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br J Clin Pharmacol 1997;44:190-194
    • (1997) Br J Clin Pharmacol , vol.44 , pp. 190-194
    • Eagling, V.A.1    Back, D.J.2    Barry, M.G.3
  • 5
    • 0031751330 scopus 로고    scopus 로고
    • Clinical pharmacokinetics and interactions with other anti-HIV agents
    • ▶5. Hsu A, Granneman GR, Bertz RJ. Clinical pharmacokinetics and interactions with other anti-HIV agents. Clin Pharmacokinet 1998;35:275-291
    • (1998) Clin Pharmacokinet , vol.35 , pp. 275-291
    • Hsu, A.1    Granneman, G.R.2    Bertz, R.J.3
  • 8
    • 0021812823 scopus 로고
    • Midazolam, the first water-soluble benzodiazepine: Pharmacology, pharmacokinetics, and efficacy in insomnia and anesthesia
    • Kanto JH. Midazolam, the first water-soluble benzodiazepine: pharmacology, pharmacokinetics, and efficacy in insomnia and anesthesia. Pharmacotherapy 1985;5:138-155
    • (1985) Pharmacotherapy , vol.5 , pp. 138-155
    • Kanto, J.H.1
  • 9
    • 0028114619 scopus 로고
    • Use of midazolam as a human cytochrome P450 3A probe. I. in vitro-in vivo correlations in liver transplant patients
    • Thummel KE, Shen DD, Podoll TD, et al. Use of midazolam as a human cytochrome P450 3A probe. I. In vitro-in vivo correlations in liver transplant patients. J Pharmacol Exp Ther 1994;271:549-556
    • (1994) J Pharmacol Exp Ther , vol.271 , pp. 549-556
    • Thummel, K.E.1    Shen, D.D.2    Podoll, T.D.3
  • 10
    • 0020529025 scopus 로고
    • Relationship between plasma concentration and effect of midazolam after oral and intravenous administration
    • Crevoisier C, Ziegler WH, Eckert M, Heizmann P. Relationship between plasma concentration and effect of midazolam after oral and intravenous administration. Br J Clin Pharmacol 1983;16(suppl 1):S51-61.
    • (1983) Br J Clin Pharmacol , vol.16 , Issue.SUPPL. 1
    • Crevoisier, C.1    Ziegler, W.H.2    Eckert, M.3    Heizmann, P.4
  • 11
    • 0026611310 scopus 로고
    • Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite alpha-hydroxymidazolam in healthy volunteers
    • Mandema JW, Tuk B, van Steveninck AL, Breimer DD, Cohen AF, Danhof M. Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite alpha-hydroxymidazolam in healthy volunteers. Clin Pharmacol Ther 1992;51:715-728
    • (1992) Clin Pharmacol Ther , vol.51 , pp. 715-728
    • Mandema, J.W.1    Tuk, B.2    Van Steveninck, A.L.3    Breimer, D.D.4    Cohen, A.F.5    Danhof, M.6
  • 12
    • 0028234586 scopus 로고
    • Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily
    • ▶12. Gorski JC, Hall SD, Jones DR, VandenBranden M, Wrighton SA. Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochem Pharmacol 1994;47:1643-1653
    • (1994) Biochem Pharmacol , vol.47 , pp. 1643-1653
    • Gorski, J.C.1    Hall, S.D.2    Jones, D.R.3    VandenBranden, M.4    Wrighton, S.A.5
  • 14
    • 59749096917 scopus 로고    scopus 로고
    • Drug-drug interaction study of ketoconazole and ritonavir-boosted saquinavir
    • ▶14. Kaeser B, Zhang X, Zandt H, et al. Drug-drug interaction study of ketoconazole and ritonavir-boosted saquinavir. Antimicrob Agents Chemother 2009;53:609-614
    • (2009) Antimicrob Agents Chemother , vol.53 , pp. 609-614
    • Kaeser, B.1    Zhang, X.2    Zandt, H.3
  • 15
    • 0032807936 scopus 로고    scopus 로고
    • Effect of saquinavir on the pharmacokinetics and pharmacodynamics of oral and intravenous midazolam
    • ▶15. Palkama VJ, Ahonen J, Neuvonen PJ, Olkkola KT. Effect of saquinavir on the pharmacokinetics and pharmacodynamics of oral and intravenous midazolam. Clin Pharmacol Ther 1999;66:33-39
    • (1999) Clin Pharmacol Ther , vol.66 , pp. 33-39
    • Palkama, V.J.1    Ahonen, J.2    Neuvonen, P.J.3    Olkkola, K.T.4
  • 16
    • 57749197592 scopus 로고    scopus 로고
    • Dose-response of ritonavir on hepatic CYP3A activity and elvitegravir oral exposure
    • ▶16. Mathias AA, West S, Hui J, Kearney BP. Dose-response of ritonavir on hepatic CYP3A activity and elvitegravir oral exposure. Clin Pharmacol Ther 2009;85:64-70.
    • (2009) Clin Pharmacol Ther , vol.85 , pp. 64-70
    • Mathias, A.A.1    West, S.2    Hui, J.3    Kearney, B.P.4
  • 17
    • 0029738490 scopus 로고    scopus 로고
    • First-pass metabolism of midazolam by the human intestine
    • ▶17. Paine MF, Shen DD, Kunze KL, et al. First-pass metabolism of midazolam by the human intestine. Clin Pharmacol Ther 1996;60:14-24.
    • (1996) Clin Pharmacol Ther , vol.60 , pp. 14-24
    • Paine, M.F.1    Shen, D.D.2    Kunze, K.L.3
  • 18
    • 33745433348 scopus 로고    scopus 로고
    • Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers
    • Yeh RF, Gaver VE, Patterson KB, et al. Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers. J Acquir Immune Defic Syndr 2006;42:52-60.
    • (2006) J Acquir Immune Defic Syndr , vol.42 , pp. 52-60
    • Yeh, R.F.1    Gaver, V.E.2    Patterson, K.B.3
  • 21
    • 0032700543 scopus 로고    scopus 로고
    • Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: Effect of ketoconazole
    • ▶21. Tsunoda SM, Velez RL, von Moltke LL, Greenblatt DJ. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole. Clin Pharmacol Ther 1999;66:461-471
    • (1999) Clin Pharmacol Ther , vol.66 , pp. 461-471
    • Tsunoda, S.M.1    Velez, R.L.2    Von Moltke, L.L.3    Greenblatt, D.J.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.